News from regenerx biopharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 13, 2023, 08:04 ET First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection,...

Apr 11, 2023, 16:59 ET RegeneRx Issues Letter To Stockholders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue...

Jan 31, 2023, 08:30 ET Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection,...

Jan 03, 2023, 08:14 ET Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection,...

Oct 24, 2022, 10:55 ET RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection,...

Sep 27, 2022, 12:24 ET RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection,...

Aug 22, 2022, 08:30 ET RegeneRx Issues 2022 Letter To Stockholders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue...

Jul 18, 2022, 08:30 ET RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection,...

Jun 22, 2022, 08:30 ET RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection,...

May 04, 2022, 10:29 ET Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and...

Mar 02, 2022, 08:30 ET RegeneRx Provides Regulatory Update Regarding RGN-259

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Feb 11, 2022, 08:23 ET RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and...

Jan 25, 2022, 08:30 ET Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and...

Jan 12, 2022, 09:30 ET RegeneRx Publishes Regulatory Update on RGN-259

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue...

Dec 17, 2021, 09:43 ET RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Nov 29, 2021, 08:30 ET RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Oct 29, 2021, 11:08 ET Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Oct 06, 2021, 09:20 ET Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Oct 05, 2021, 08:30 ET New Research Demonstrates Thymosin Beta 4's Potential Positive Effects on Alzheimer's Disease

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Sep 27, 2021, 08:30 ET RegeneRx Licensee Acquired by Korean Biopharmaceutical Group

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Jul 22, 2021, 08:30 ET RegeneRx Issues Letter To Stockholders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue...

Jul 14, 2021, 08:07 ET RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Jul 01, 2021, 13:00 ET RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

Jun 28, 2021, 16:15 ET RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...

May 14, 2021, 08:30 ET RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and...